NASDAQ:PLSE Pulse Biosciences Q3 2026 Earnings Date & Estimates $52.66 -0.36 (-0.68%) Closing price 04:00 PM EasternExtended Trading$52.54 -0.12 (-0.23%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Pulse Biosciences is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Pulse Biosciences in Q3 2026Pulse Biosciences is expected to post earnings of -$0.3095 per share on revenue of $521 thousand. In the same quarter a year earlier Pulse Biosciences reported -$0.29 per share. Pulse Biosciences last reported on August 6, 2026, posting -$0.36 per share and missing the -$0.2933 consensus estimate. Pulse Biosciences has beaten the consensus EPS estimate in 3 of its last 5 quarters.Consensus EstimatesConsensus EPS-$0.3095Expected Revenue$521 thousandPrior-Year EPS-$0.29Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.36 (Missed by -$0.0667)Last Quarter Revenue$434 thousandEPS Beat Rate3 of last 5 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Pulse Biosciences Q3 2026 Earnings FAQ When does Pulse Biosciences report Q3 2026 earnings? Pulse Biosciences (NASDAQ:PLSE) has confirmed it will report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. What time is Pulse Biosciences' Q3 2026 earnings call? Pulse Biosciences' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Pulse Biosciences? Analysts expect Pulse Biosciences to post earnings of -$0.3095 per share for Q3 2026. How much revenue is Pulse Biosciences expected to report? The consensus revenue estimate for Pulse Biosciences is $521 thousand for Q3 2026. Pulse Biosciences Earnings HeadlinesPulse Biosciences (PLSE) Stock Still Seems Rich Against Book ValueOctober 25 at 9:22 AM | finance.yahoo.comPulse Biosciences consensus price target increased by 15.43% to $63.58October 23 at 7:14 AM | msn.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.October 26 at 1:00 AM | Weiss Ratings (Ad)Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026October 22, 2026 | businesswire.comPulse Biosciences (PLSE) Stock Fair Value Rises After Analyst Target IncreasesOctober 17, 2026 | finance.yahoo.comPulse Biosciences Announces Commercial and Clinical Partnership with the Clayman Thyroid CenterOctober 14, 2026 | marketscreener.comMSee More Pulse Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pulse Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulse Biosciences and other key companies, straight to your email. Email Address About Pulse BiosciencesPulse Biosciences (NASDAQ:PLSE). (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue. The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions. Pulse Biosciences is also developing NPS applications in other areas of medicine, including cardiac procedures, where its technology is being investigated for nonthermal tissue ablation. Founded in 2014 and headquartered in Hayward, California, Pulse Biosciences has focused on developing and commercializing its platform in the United States while pursuing additional regulatory clearances and market opportunities internationally. The company is led by President and Chief Executive Officer Burke T. Barrett.View Pulse Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Anthropic's IPO Filing Reveals a Massive Opportunity for AI Infrastructure GiantsBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBuy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big CatalystsComfort Systems Earnings: AI Slowdown or More Growth Ahead?MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline Upcoming Earnings Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Baker Hughes (10/27/2026)ONEOK (10/27/2026)Robinhood Markets (10/27/2026)HSBC (10/27/2026)S&P Global (10/27/2026)Visa (10/27/2026)HCA Healthcare (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
